Trial document




drksid header

  DRKS00000633

Trial Description

start of 1:1-Block title

Title

GLIAA-Pilot: Amino-acid PET versus MRI guided tumor volume delineation followed by re-irradiation in patients with recurrent glioblastoma multiforme
- A feasibility trial

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

GLIAA-Pilot

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Scientists at the divisions of radio-oncology, nuclear medicine and medical oncolgy are collaborating in the GLIAA-Clinical Trial on optimizing the treatment of brain tumors and especially of Glioblastomas (Glioblastoma multiforme).
For the tumor volume delineation for radiotherapy treatment two different imaging methods are used: 1) Gadolinium contrast enhanced T1 weighted Magnetic Resonance Imaging (T1Gd-MRI) and 2) Amino-acid positron emission tomography (AA-PET) with [methyl-11C]-L-methionine (MET) or O-(2-[18F]) fluoroethyl)-L-tyrosine (FET).
Both methods allow the differentiation of tumor tissue from normal brain tissue.
The aim of this clinical trials is to evaluate the
difference between AA-PET-based radiotherapy target volumes versus MRI-based radiotherapy target volumes. Additionally the
impact of radiotherapy target volume delineation based on AA-PET on the effect on target volumes and the clinical outcome of patients with recurrent glioblastoma (GBM) will be compared to target volume delineation based on contrast enhanced T1 weighted MRI (T1Gd-MRI).
The goal ist to evaluate the best way to integrate these imaging methods and to optimize radiotherapy treatment based on these results.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

This study is designed to test in patients with recurrent GBM treated with re-irradiation based on Amino-acid positron emission tomography (AA-PET) with O-(2-[18F]) fluoroethyl)-L-tyrosine (FET) and Gadolinium contrast enhanced T1 weighted Magnetic Resonance Imaging (T1Gd-MRI) if a tumor volume delineation based on AA-PET differs from tumor volume delineation based on T1Gd-MRI in a sufficient proportion of patients to justify further research into a comparison of AA-PET versus MRI guided radiotherapy.
All patients will recieve radiotherapy based on both imaging methods, with a fracionation of 5x3Gy per week upt to a total dose of 39Gy.
Primary objective is the volumetrical assessment of delineated gross tumor volume (GTV) based on AAPET vs. delineated GTV based on T1Gd-MRI and its correlation with AA-PET/MRI non-overlap in ml.
As secondary objectives, prospective survival data as well as data on topography of recurrent tumors and radiotherapy toxicities, including radionecrosis, will be collected. New MRI sequences like diffusion and perfusion MRI will be compared with the AA-PET images. A QA program will be established during this trial.
The protocol was resubmitted to the ethics committee Freiburg in May 2012, due to the modification of performing the radiation treatment according to clinical standards an not after randomization (treatment planning based on MRI versus AA-PET) (Amendment 1). The ethics committee Freiburg approved of the modification (Approval 23.05.2012, No. 224/10_120430).

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00000633
  •   2010/12/08
  •   [---]*
  •   yes
  •   Approved
  •   224/10, Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   U1111-1118-4662 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   C71 -  Malignant neoplasm of brain
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   All patients will recieve the same radiotherapy independent of participation in the study.
    Target volume delineation will be based on AA-PET and T1-Gd-MRI: GTV = AA uptake on PET respectively Gd-contrast enhancement on T1-Gd-MRI, clinical target volume (CTV) = GTV + 3mm, PTV = CTV + 2mm followed by high-precision re-irradiation (stereotactic fractionated radiation therapy (SFRT) and/or image guided radiation therapy (IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week.
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Observational study
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Other
  •   Single (group)
  •   N/A
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Relevant AA-PET/MRI non-overlap (yes/no), defined as non-overlapping tumor volume of AA-PET and MRI ≥ 2ml.
Let p denote the probability of relevant AA-PET/MRI non-overlap. The study is designed to test the null-hypothesis H0: p ≤ 25% against the alternative hypothesis H1: p > 25% at significance level 5%. This will be done by an exact one-sided binomial test (analysis of the primary endpoint).

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Progression Free Survival (PFS),
Overall Survival (OS), topography of recurrence,
localization of necrosis after re-irradiation,
comparison of acute and late toxicity.
Impact of diffusion/perfusion MRI on target volume delineation.

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • [---]*
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2010/12/12
  •   30
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

- Local recurrence of Glioma / GBM (WHO grade IV) and either not eligible for tumor resection or with macroscopic residual tumor after resection of recurrent GBM
- Recurrent tumor visible on AA-PET and MRI-T1-Gd with the diameter measuring 1 cm to 6 cm by either technique
- Target volume definition possible according to both study arms
- Previous radiation therapy of the primary with a maximal total dose 60 Gy
- At least 6 months since the end of pre-irradiation and start of re-irradiation
- At most 2 prior chemotherapy regimes
- Start of radiation therapy possible within 3 weeks from AA-PET
- Karnofsky Performance Score (KPS) >60%
- Age ≥ 18 years
- Written informed consent (IC) obtained

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- No histological confirmation of GBM
- Recent (≤ 4 weeks before IC) histological result showing no tumor recurrence
- No recurrent tumor detectable on last AA-PET or MRI-T1-Gd
- Technical impossibility to use existing AA-PET for RT-planning
- No prior radiation treatment to the primary tumor
- less than 6 months between the end of first radiation treatment and start of re-irradiation
- more than 2 previous chemotherapy regimes or previous treatment with Avastin or other molecular targeted therapies
- less than 2 weeks between application of chemotherapy and start of re-irradiation
- additional chemotherapy or molecular targeted therapy or further surgery planned before diagnosis of further tumor progression after study intervention
- pregnancy, nursing or patient not willing to prevent pregnancy during treatment

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Klinik für Strahlenheilkunde Universitätsklinik Freiburg
    • Ms.  Prof. Dr. med.  Anca-Ligia  Grosu 
    • Robert-Koch-Str. 3
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Klinik für Strahlenheilkunde Universitätsklinik Freiburg
    • Ms.  Prof. Dr. med.  Anca-Ligia  Grosu 
    • Robert-Koch-Str. 3
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Klinik für Strahlenheilkunde Universitätsklinik Freiburg
    • Ms.  Tanja  Schimek-Jasch 
    • Robert-Koch-Str. 3
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Tumorzentrum Ludwig Heilmeyer - CCCF Universitätsklinikum Freiburg
    • Hugstetter Straße 55
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up complete
  •   2015/06/30
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.